United Therapeutics (UTHR) Stock: Buy, Sell, or Hold?
UTHR - United Therapeutics Corp
$497.11
-6.75 (-1.34%)
▼
5d:
+1.4%
30d:
-2.86%
90d:
-8.85%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Sep 10, 2026 at $503.86 · last confirmed Sep 11, 2026
Strength: 4.6/10
Get Alerted When UTHR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: UTHR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: UTHR shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$690.66
Based on 7.1% avg growth
INTRINSIC VALUE TODAY
$428.84
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UTHR is currently trading at $497.11, which is considered oversold relative to its 30-day fair value range of $499.62 to $525.20. The stock's valuation (Forward PE: 17.3) is in line with its historical norms (17.1). At these levels, the market is pricing in 0.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, UTHR is in a strong downtrend. Immediate support is located at $477.01, while resistance sits at $530.50.
Market Sentiment: UTHR scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $664.33 (+33.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UTHR is in a strong downtrend. Immediate support is located at $477.01, while resistance sits at $530.50.
Market Sentiment: UTHR scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $664.33 (+33.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$499.62 -
$525.20
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
93.1%
Protect Your Profits
Holding UTHR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 33.6% below Wall St target ($664.33)
- NEUTRAL: Market pricing in 0.4% annual earnings growth - fairly valued
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$499.62 -
$525.20
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$25.02
(5.0%)
Support & Resistance Levels
Support Level
$477.01
Resistance Level
$530.50
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.33
Wall Street Target
$664.33
(+33.6%)
Revenue Growth (YoY)
-1.9%
Earnings Growth (YoY)
13.4%
Profit Margin
41.6%
Valuation Premium vs History
+0.4% premium
PE vs Historical
17.3 vs 17.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.4%
(market-implied from PE analysis)
1-Year Target
$499.10
(+0%)
2-Year Target
$501.09
(+1%)
3-Year Target
$503.10
(+1%)
3-Yr Target (if PE normalizes)
(PE: 17→17)
PE COMPRESSION
$496.56
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 10.2%)
$774.09
(+56%)
Base:
(SPY PE: 17.3, Growth: 10.2%)
$664.91
(+34%)
Bear:
(PE: 14.7, Growth: 10.2%)
$565.17
(+14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 18.04 | Current EPS (TTM): $27.93
Bull Case
$569.39
(+15%)
Analyst growth 2.7%, PE expands to 19.8
Base Case
$517.62
(+4%)
Market implied 2.7%, PE stable at 18.0
Bear Case
$342.62
(-31%)
Severe decline -20.0%, PE contracts to 15.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 9:37 AM ET
Data refreshes hourly during market hours. Next update: 10:37 AM
Data refreshes hourly during market hours. Next update: 10:37 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UTHR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Patusky
SELL
2910 shares
2026-04-24
James Edgemond
SELL
9636 shares
2026-04-23
James Edgemond
SELL
364 shares
2026-04-22
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
Advanced UTHR Option Strategies
Professional options setups generated by AI based on today's UTHR price and gamma walls.
